Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Investor's Business Daily on MSN
Eli Lilly Rises, Again, After EMA Groups Recommends Mounjaro For Children As Young As 10
On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young ...
The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
Dec 12 (Reuters) - The European Medicines Agency's committee on Friday recommended extending the use of Eli Lilly's ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
The European Medicines Agency's committee on Friday recommended extending the use of Eli Lilly's blockbuster drug Mounjaro ...
Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...
Regulators voted Thursday to extend a shutdown preventing New England fishermen from catching shrimp, a historic industry ...
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback